AstraZeneca is actively seeking more drug deals to fill its pipeline, despite a spree of acquisitions and licensing agreements over the past year, its head of development said on Tuesday.
"We're not going to stop looking -- it isn't a one-off tactical issue. This is a strategic move to access the big world of science out there," John Patterson said on the sidelines of a Financial Times pharmaceuticals conference.
"We know from our own labs that we have a too thin a phase II portfolio today given the attrition (failure) rates," he added.
Patterson said the shift in emphasis to more external alliances marked a culture change for scientists at AstraZeneca.
"It has been a bit of a challenge within AstraZeneca, which traditionally, of all the big pharma companies, I think believed it could invent its way out any kind of corner," he said.
Reuters
"We're not going to stop looking -- it isn't a one-off tactical issue. This is a strategic move to access the big world of science out there," John Patterson said on the sidelines of a Financial Times pharmaceuticals conference.
"We know from our own labs that we have a too thin a phase II portfolio today given the attrition (failure) rates," he added.
Patterson said the shift in emphasis to more external alliances marked a culture change for scientists at AstraZeneca.
"It has been a bit of a challenge within AstraZeneca, which traditionally, of all the big pharma companies, I think believed it could invent its way out any kind of corner," he said.
Reuters
Insider's view: good for you John!
Never let it be said that you were one of the dinosaurs who believed that "old school" rubbish of "no good - not invented here"!
No comments:
Post a Comment